Brought to you by 
Enanta Pharmaceuticals gets $20mm with second round
14 Aug 2000
Executive Summary
Enanta (small-molecule drugs) got $20mm in its second round of financing. Participants included lead investor Oxford Bioscience Partners; Advent International; TVM Techno Venture Management; Caduceus Capital; Bank Vontobel; Alpinvest International; and KB Lux Venture Capital.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Enanta Pharmaceuticals gets $20mm with second round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice